CYCLOTRONS2022 - List of Authors (Abs, M.)

Paper	Title	Page
WEAO03	Development of the Cyclone® Key: How Interoperability Leads to Compactness	156
	V. Nuttens, M. Abs, J. Caulier, Q. Flandroy, W.J.G.M. Kleeven, E.K. Kral, J. Mandrillon, O. Michaux, N.A.R. Mine, E. van der Kraaij IBA, Louvain-la-Neuve, Belgium
	Funding: Pole Mecatech/Biowin/SPW RW - Convention 8150: CardiAmmonia In 2020, IBA has started the design, construction, tests and industrialization of a new proton cyclotron for the low energy range, the Cyclone® KEY, for PET isotope production (18F, 13N, 11C) for neurology, cardiology or oncology imaging. It is a compact and fully automated isochronous cyclotron accelerating H⁻ up to 9,2 MeV. Based on the successful design history and return of experience of the Cyclone® KIUBE, the Cyclone® KEY design has been focused on compactness (self-shielding enabled), cost effectiveness and ease of installation, operation and maintenance. The innovative design consists in the interoperability of the different subsystems: the magnet, the RF system, the vacuum system, the ion source, the stripping extraction, and target changers (with up to three targets). First beam tests results will also be presented.
	Slides WEAO03 [2.848 MB]
DOI •	reference for this paper ※ doi:10.18429/JACoW-CYCLOTRONS2022-WEAO03
About •	Received ※ 22 December 2022 — Revised ※ 11 January 2023 — Accepted ※ 01 February 2023 — Issue date ※ 11 April 2023
Cite •	reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)

THBI01	Status on NHa C400 Cyclotron for Hadrontherapy	264
	J. Mandrillon, M. Abs, P. Cailliau, S. Deprez, X. Donzel, G. Goosse, Y. Jongen, W.J.G.M. Kleeven, L.C.L. Koffel, V. Nuttens, Y. Otu, Y. Paradis IBA, Louvain-la-Neuve, Belgium O. Cosson, L. Maunoury, Ph. Velten NHa, Caen, France
	C400 is an isochronous cyclotron for cancer therapy delivering high dose rates of alphas to carbons at 400 MeV/amu extracted by electrostatic deflector and protons at 260 MeV extracted by stripping of molecular hydrogen. IBA started to pre-design the system more than 13 years ago in collaboration with JINR. The responsibility for the development of C400 has meanwhile been taken over by the French company Normandy Hadontherapy (NHa). However, the study and design work continued with a very strong involvement of IBA for the past 3 years, from concept on paper to reality. We will describe the most innovative concepts and technical solutions on the accelerator from source to extraction and show the construction progress.
	Slides THBI01 [6.375 MB]
DOI •	reference for this paper ※ doi:10.18429/JACoW-CYCLOTRONS2022-THBI01
About •	Received ※ 08 December 2022 — Revised ※ 12 January 2023 — Accepted ※ 31 January 2023 — Issue date ※ 18 February 2023
Cite •	reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)

Paper

Title

Page

Development of the Cyclone® Key: How Interoperability Leads to Compactness

156

V. Nuttens, M. Abs, J. Caulier, Q. Flandroy, W.J.G.M. Kleeven, E.K. Kral, J. Mandrillon, O. Michaux, N.A.R. Mine, E. van der Kraaij
IBA, Louvain-la-Neuve, Belgium

Funding: Pole Mecatech/Biowin/SPW RW - Convention 8150: CardiAmmonia
In 2020, IBA has started the design, construction, tests and industrialization of a new proton cyclotron for the low energy range, the Cyclone® KEY, for PET isotope production (18F, 13N, 11C) for neurology, cardiology or oncology imaging. It is a compact and fully automated isochronous cyclotron accelerating H⁻ up to 9,2 MeV. Based on the successful design history and return of experience of the Cyclone® KIUBE, the Cyclone® KEY design has been focused on compactness (self-shielding enabled), cost effectiveness and ease of installation, operation and maintenance. The innovative design consists in the interoperability of the different subsystems: the magnet, the RF system, the vacuum system, the ion source, the stripping extraction, and target changers (with up to three targets). First beam tests results will also be presented.

Slides WEAO03 [2.848 MB]

DOI •

reference for this paper ※ doi:10.18429/JACoW-CYCLOTRONS2022-WEAO03

About •

Received ※ 22 December 2022 — Revised ※ 11 January 2023 — Accepted ※ 01 February 2023 — Issue date ※ 11 April 2023

Cite •

reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)

THBI01

Status on NHa C400 Cyclotron for Hadrontherapy

264

J. Mandrillon, M. Abs, P. Cailliau, S. Deprez, X. Donzel, G. Goosse, Y. Jongen, W.J.G.M. Kleeven, L.C.L. Koffel, V. Nuttens, Y. Otu, Y. Paradis
IBA, Louvain-la-Neuve, Belgium
O. Cosson, L. Maunoury, Ph. Velten
NHa, Caen, France

C400 is an isochronous cyclotron for cancer therapy delivering high dose rates of alphas to carbons at 400 MeV/amu extracted by electrostatic deflector and protons at 260 MeV extracted by stripping of molecular hydrogen. IBA started to pre-design the system more than 13 years ago in collaboration with JINR. The responsibility for the development of C400 has meanwhile been taken over by the French company Normandy Hadontherapy (NHa). However, the study and design work continued with a very strong involvement of IBA for the past 3 years, from concept on paper to reality. We will describe the most innovative concepts and technical solutions on the accelerator from source to extraction and show the construction progress.

Slides THBI01 [6.375 MB]

DOI •

reference for this paper ※ doi:10.18429/JACoW-CYCLOTRONS2022-THBI01

About •

Received ※ 08 December 2022 — Revised ※ 12 January 2023 — Accepted ※ 31 January 2023 — Issue date ※ 18 February 2023

Cite •

reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)